AI drug discovery platform for neuroscience using multimodal patient brain data to identify targets, stratify patients, and shrink clinical trial size.
Verge Labs builds frontier AI foundation models for neurological disease drug discovery, trained on one of the world's largest proprietary multimodal patient brain datasets — deep molecular profiling on 12,000+ brains across 6,000 patients plus 900+ frozen tissue samples. The platform generates virtual biopsies of patient brain biology from routine blood draws, enabling target discovery, biomarker identification, and patient stratification. In a Parkinson's demonstration, the platform lifted L-DOPA responder enrichment from 52% to 69%, reducing required enrollment by 43% at fixed statistical power. Verge Labs is a product of Verge Genomics.